Trending News
News
News
Aegis Therapeutics LLC Awarded Patent for Parathyroid Hormone (PTH) Peptide Drug Formulations
The company announced that it has been awarded U.S. Patent No. 8,076,290, providing broad protection for stabilized formulations suitable for all routes of administration, including the non-invasive metered nasal spray delivery route or injection.
News
Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)
The company announced it has initiated a Phase I study in healthy volunteers with ALX- 0171, the first Nanobody in clinical development to be delivered by inhalation.
News
Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH
Phase 2 data demonstrate that rozrolimupab induce a rapid increase in blood platelets of ITP patients.
News
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011
Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported.
News
Paladin Labs Announces the Canadian Launch of DigiFab™ Digoxin Immune Fab (Ovine)
DigiFab™ is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose.
News
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
The company announced that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational “Zamore Design Rule” patent families.
News
New Protocols Improve Detection of MicroRNAs for Diagnosis
MicroRNAs (miRNAs) that regulate processes including fertilization, development, and aging show promise as biomarkers of disease. They can be collected from routinely collected fluids such as blood, saliva, and urine.
News
Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial
Sunesis Pharmaceuticals, Inc. has announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed a planned periodic safety review and recommended that the trial continue as planned without changes to study conduct.
News
Auxilium Pharmaceuticals, Inc. Appoints Adrian Adams Chief Executive Officer and President
Mr. Adams succeeds Armando Anido, who, after discussions with the Company's Board of Directors, has agreed to step down as Chief Executive Officer and President and has resigned as a member of the Board of Directors. Mr. Adams has also been appointed to the Company's Board of Directors.
News
CYTOO, Cenix BioScience and Academic Collaborators Receive 4 M€ EU FP7 Grant to Launch MEHTRICS Consortium
New public-private consortium to further develop the power of high throughput, high content RNAi screening through convergence with micropatterning-based cell assays.
Advertisement